Brian Bergmark News Today

In Bridge-TIMI 73a and SHASTA-2, the RNA-silencing therapies cut triglycerides quickly, offering hope for hard-to-treat patients.

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

Results show drug is effective and safe, leaves open question of optimal dosing

Dr Erin D. Michos provides highlights from ACC 2024, including anticipated presentations, quick takeaways, and insights into how the presented research will impact patients.

/PRNewswire/ -- Stout announced the acquisition of Torrey Partners, an economic, forensic accounting, and valuation services firm headquartered in San Diego,...

The results line up with an all-comers analysis and point to an evolving understanding of how to treat LM CAD, say experts.

The findings provide insight into the relationship between cardiovascular biomarkers, coronary anatomical complexity, and incident clinical events.

Researchers hold little hope for this compound, which had a poor safety profile, but suggest the ANGPTL3 story isn’t over.

An investigational antisense oligonucleotide drug targeting a novel cholesterol pathway showed disappointing results in this phase 2b study.